比利时人群皮肤癌筛查的成本效果与预算影响分析
该研究基于比利时2014年临床试验,用Markov模型(潜伏期20年、时限50年)比较两种人群皮肤癌筛查方案与不筛查的成本效果和预算影响。两种筛查均获得QALY增益,全身皮肤检查(TBSE)在男性中每QALY成本€33 072、女性€18 687,病灶导向筛查(LDS)男性€34 836、女性€19 470;一次性筛查使III/IV期黑色素瘤发病率降低4.0%。
要点
- TBSE和LDS两种筛查策略均产生QALY增益,女性成本效果优于男性。
- 一次性筛查预测使III/IV期黑色素瘤发病率降低4.0%。
- 在比利时€35 000/QALY支付意愿阈值下,筛查可视为具有成本效果。
核心结论
- 在比利时€35 000每QALY的支付意愿阈值下,两种人群皮肤癌筛查策略均具有成本效果。
- 一次性TBSE是成本效果最优策略,预测可降低20年和50年皮肤癌死亡率。
- 皮肤癌筛查的成本效果女性高于男性。
研究设计与样本
- 采用Markov模型,潜伏期20年、时间跨度50年,分析成本效果(社会视角)和预算影响(公共医疗支付方视角)。
- 基于2014年比利时临床试验,假设邀请全国18岁及以上人群参加筛查。
- 比较两种人群筛查方案(TBSE和LDS)与不筛查方案。
主要发现
- TBSE每QALY增量成本:男性€33 072(US $35 475),女性€18 687(US $20 044)。
- LDS每QALY增量成本:男性€34 836(US $37 365),女性€19 470(US $20 884)。
- 一次性筛查预测使III/IV期黑色素瘤发病率相对下降4.0%。
- 20年内一次性TBSE的净成本约€36 million(US $38.6 million),LDS约€6 million(US $6.4 million)。
- 人均净成本:TBSE €4.1(US $4.40),LDS €0.7(US $0.80)。
关键数值与推荐
- 成本效果可接受阈值:比利时€35 000(US $37 541)每QALY。
- TBSE和LDS的增量成本效果比(ICER)范围:男性€33 072–€34 836/QALY,女性€18 687–€19 470/QALY。
- 一次性筛查使III/IV期黑色素瘤发病率相对降低4.0%。
临床怎么用
- 在比利时背景下,对18岁及以上成人可考虑一次性TBSE作为最具成本效果的人群筛查策略。
- 筛查实施需考虑性别差异,女性筛查的成本效果更高。
- 决策者可将€35 000/QALY作为支付意愿阈值参考。
局限性
- 经济模型基于2014年比利时单次临床试验数据,外推需谨慎。
- 模型假设全国18岁及以上人群均被邀请筛查,实际参与率可能影响结果。
- 未报告长期随机对照试验验证筛查对死亡率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Several epidemiological studies show an alarming global increase in incidence of melanoma and nonmelanoma skin cancer. OBJECTIVES: To examine the cost-effectiveness of 2 population-based skin cancer screening methods and to assess their budget effect and the influence on skin cancer epidemiological findings. DESIGN, SETTING, AND PARTICIPANTS: A Markov model with a latent period of 20 years and a time horizon of 50 years was used to analyze the cost-effectiveness (societal perspective) and budget effect (public health care payer perspective) of 2 population-based skin cancer screening programs in Belgium compared with the absence of a screening program. A health economic analysis was based on a clinical trial performed in 2014 in Belgium. In the economic model, the total Belgian population 18 years or older was assumed to have been invited for the screening program. MAIN OUTCOMES AND MEASURES: The influence of the screening program on skin cancer epidemiological findings and the cost per quality-adjusted life-year (QALY) gained, as well as the budget effect, expressed as the net costs for the health care payer over 50 years. RESULTS: All participants (1668 total-body skin examination [TBSE] and 248 lesion-directed screening [LDS]) were screened by a team of 6 dermatologists from March 14 to 18, 2014, for TSBE and April 22 and 25 to 27, 2014, for LDS. Both screening strategies produced a gain in QALYs, resulting in incremental cost-effectiveness ratios of €33 072 (US $35 475) per QALY in men and €18 687 (US $20 044) per QALY in women for TBSE and €34 836 (US $37 365) per QALY in men and €19 470 (US $20 884) per QALY in women for LDS. With a 1-time screening, a 4.0% decrease in the incidence rates of stage III and IV melanoma was predicted at the population level relative to the comparator. The budget effect analysis demonstrated that during 20 years, a 1-time screening would incur a net cost for the health care payer of almost €36 million (US $38.6 million) for TBSE or just over €6 million (US $6.4 million) for LDS (€4.1 [US $4.40] or €0.7 [US $0.80], respectively, per adult). CONCLUSIONS AND RELEVANCE: These results can be interpreted as cost-effective at a willingness-to-pay threshold in Belgium of €35 000 (US $37 541) per QALY gained. Based on these findings, a 1-time TBSE in the general adult population 18 years or older is the most cost-effective strategy and is predicted to result in a reduction of skin cancer mortality over 20 years and 50 years. The cost-effectiveness for skin cancer screening is higher in women than in men.
引用
- Pil L, Hoorens I, Vossaert K, et al. Cost-effectiveness and Budget Effect Analysis of a Population-Based Skin Cancer Screening. JAMA Dermatol. 2017. PMID: 28002834. doi:10.1001/jamadermatol.2016.4518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。